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Abstract 46 
Ophthalmoplegia/ophthalmoparesis (internal, external, or both) has been reported in dogs 47 
secondary to neoplasia affecting the oculomotor nerve and is usually given a poor 48 
prognosis. The purpose of this retrospective study was to describe the clinical findings, 49 
magnetic resonance imaging (MRI), management, outcome and follow-up of canine cases 50 
with idiopathic oculomotor neuropathy. Inclusion criteria included cases with 51 
ophthalmoplegia/ophthalmoparesis (internal, external or both) as sole neuro-52 
ophthalmologic sign, complete ophthalmic and neurologic examination, head MRI, and a 53 
minimum follow-up of one year. Dogs with progressive neurological signs not related 54 
with oculomotor neuropathy were excluded. Fourteen cases met the inclusion criteria. All 55 
cases were unilaterally affected. Magnetic resonance imaging showed equivocal 56 
enlargement of the oculomotor nerve in three cases, mild enlargement in five and marked 57 
enlargement in six. Contrast enhancement was present in twelve cases, being marked in 58 
six. When present, the contrast enhancement was focal in eight cases and diffuse in four. 59 
The median follow-up time was 25 months. External ophthalmoparesis improved in 60 
seven cases, five cases under no treatment and two under systemic corticosteroid therapy. 61 
The clinical signs in the other seven cases remained unchanged. Idiopathic oculomotor 62 
neuropathy should be included as a differential diagnosis in dogs presenting with 63 
unilateral ophthalmoplegia/ophthalmoparesis (internal, external, or both) with the 64 
absence of other neurologic and ophthalmic signs, and with the MRI findings restricted to 65 
the oculomotor nerve. Idiopathic oculomotor neuropathy has a good prognosis as the 66 
clinical signs do not deteriorate and they can improve without treatment.  67 
 68 
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Introduction 69 
The oculomotor nerve (cranial nerve III or CN III) innervates the ipsilateral extraocular 70 
muscles (dorsal, ventral, and medial rectus and ventral oblique muscle) and the ipsilateral 71 
levator palpebrae superioris muscle.1 Additionally, CN III controls ipsilateral pupillary 72 
constriction through its parasympathetic component.1 A complete CN III lesion (motor 73 
and parasympathetic dysfunction) causes areflexive mydriasis (internal ophthalmoplegia), 74 
a smaller palpebral fissure due to ptosis, neuromuscular dorsolateral strabismus, and the 75 
affected eye will not adduct well on testing physiological nystagmus (vestibulo-ocular 76 
reflex) (external ophthalmoparesis).2 In the veterinary literature, canine 77 
ophthalmoplegia/ophthalmoparesis (internal, external, or both) has been reported 78 
secondary to neoplasia affecting CN III at the level of the middle cranial fossa (MCF) or 79 
orbital fissure,3-12 and it is usually given a poor prognosis.2 Idiopathic trigeminal and 80 
facial neuropathy have been reported in dogs;13-17 however, idiopathic oculomotor 81 
neuropathy is currently not reported in the veterinary literature. The aims of this study 82 
were to describe the clinical findings, magnetic resonance imaging (MRI) features, 83 
management, outcome, and long-term follow-up of canine cases diagnosed with 84 
idiopathic oculomotor neuropathy. 85 
 86 
Methods 87 
Medical records of all dogs referred to the Animal Health Trust for 88 
ophthalmoplegia/ophthalmoparesis from January 1999 to December 2014 were reviewed. 89 
Inclusion criteria included all cases with ophthalmoplegia/ophthalmoparesis (internal, 90 
external or both) as sole neuro-ophthalmologic sign, complete ophthalmic and neurologic 91 
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examination, head MRI, and a minimum follow-up of one year. Dogs with progressive 92 
neurological signs not related to oculomotor neuropathy were excluded. 93 
Patient information collected included the following: age, gender, breed, duration of 94 
clinical signs prior to referral, clinical signs and affected side at presentation, MRI 95 
findings, cerebrospinal fluid (CSF) analysis, treatment, and follow-up. All MRI studies 96 
were reviewed by a board-certified veterinary neurologist (E.B.) and a board-certified 97 
veterinary radiologist (R.D.), who were unaware of the side of the clinical signs. 98 
Disagreement was resolved by a consensus reading by the two reviewers. Five MRI 99 
parameters were evaluated in each case and included the following: (1) enlargement of 100 
CN III (equivocal, mild or marked), (2) intensity at the area of CN III on T2W and T1W 101 
and also on FLAIR when available (hypointense, isointense or hyperintense), (3) post-102 
contrast enhancement at the area of CN III (none, mild or marked), (4) features of post-103 
contrast enhancement at the area of CN III (focal or diffuse enhancement and 104 
homogenous or heterogeneous enhancement), and (5) anatomical region of the lesion. 105 
The enlargement was classified as equivocal when there was uncertainty about the 106 
presence or absence of enlargement, mild when the affected CN III was enlarged 107 
compared to the contralateral but there was no mass effect to the surrounding neuropil, 108 
and marked when the affected CN III was enlarged and there was mass effect to the 109 
surrounding neuropil. The intensity of CN III on T2W was classified as hypointense 110 
when its brightness was inferior to the brightness of normal gray matter, isointense when 111 
its brightness was equal to the normal gray matter, and hyperintense when its brightness 112 
was superior to the brightness of normal gray matter. This was repeated for T1W and also 113 
for FLAIR when available. The post-contrast enhancement was categorized as mild when 114 
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there was contrast enhancement that was hypointense compared to the fat tissue on T1W 115 
images, and marked when the contrast enhancement was isointense to the fat tissue on 116 
T1W images. The contrast enhancement was classified as diffuse when detected 117 
throughout the length of CN III and focal when only present at a focal location of CN III. 118 
And finally, the contrast enhancement was categorized as homogenous when there was 119 
uniform enhancement and heterogeneous when it was dissimilar throughout the enhanced 120 
area. If follow-up MRI was available, the images were evaluated following the same 121 
parameters. 122 
For each patient, long term follow-up was performed with a combination of clinical re-123 
examinations, evaluation of the clinical records post-diagnosis and phone conversation 124 
with the owner. The referring veterinarians were contacted for the clinical history post-125 
diagnosis of the patients. The owners whose dogs were alive at the start of the study were 126 
invited for a re-examination at the Animal Health Trust. Cases re-examined received a 127 
complete ophthalmic examination by a European College of Veterinary Ophthalmologists 128 
trained ophthalmologist (R.T.P.) and neurological examination by board-certified 129 
veterinary neurologists (C.F. and E.B.). In cases of dogs either lost to follow-up, dead or 130 
not available for re-examination, the long-term follow-up was determined based on the 131 
clinical records post-diagnosis and the phone conversation with the owner. 132 
 133 
Results 134 
Signalment and Clinical Findings 135 
Fourteen cases met the inclusion criteria (Appendix 1). The mean (standard deviation, 136 
SD) and median (range) age at presentation were 6.25 years (2.3) years and 6.5 years (3 137 
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to 10 years), respectively. There were entire females (n = 1, 7%), neutered females (n = 7, 138 
50%), entire males (n = 2, 14%), and neutered males (n = 4, 29%). The distribution of the 139 
individual breeds is shown in Appendix 1, with the more commonly affected breeds 140 
being Boxer (n = 4, 29%) and Border Collie (n = 2, 14%). The mean (SD) and median 141 
(range) duration of the clinical signs prior to referral were 73 days (195) and 5 days (1 142 
day to 2 years), respectively. Cases presented with both internal and external 143 
ophthalmoplegia/ophthalmoparesis (n = 11, 79%, Fig 1.) or only internal 144 
ophthalmoplegia (n = 3, 21%). The clinical signs were unilateral in all cases, being right 145 
sided (n = 8, 57%) or left sided (n = 6, 43%).  146 
 147 
Magnetic Resonance Imaging Findings 148 
Magnetic resonance of the head was performed using a 1.5T scanner (GE Signa, GE 149 
Medical System, Milwaukee, WI, USA). Non-contiguous transverse images with a 3-5-150 
mm slice thickness and an interslice gap of 0.3-0.5 mm were generated with T1-weighted 151 
(T1W) and T2-weighted (T2W) spin echo pulse sequences in all three planes. Sequences 152 
included T1W and T2W and T1W with fat saturation (FAT-SAT). T1W FAT-SAT 153 
images were also acquired after intravenous paramagnetic contrast medium, 154 
0.05mmol/kg, gadobenate dimeglumine (Multi-Hance®, Bracco Imaging SpA, Milan 155 
Italy). T1W post contrast FAT-SAT and fast fluid-attenuation inversion recovery 156 
(FLAIR) findings were recorded when available. Magnetic resonance findings are 157 
detailed in Appendix 2. Equivocal enlargement of CN III was noted in three cases (n = 3, 158 
21%; Fig. 2), mild enlargement in five cases (n = 5, 35%; Fig. 3) and marked 159 
enlargement in six cases (n = 6, 43%; Fig. 4). The affected CN III was isointense on T2W 160 
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and T1W pre-contrast sequences in five cases (n = 5, 35%; Fig. 2), hyperintense on T2W 161 
and isointense on T1W in seven cases (n = 7, 50%; Fig. 3) and hypointense on T2W and 162 
isointense on T1W in two cases (n = 2, 14%). FLAIR sequence was available in all cases 163 
but in two dogs; the intensity on FLAIR was equal to T2W in all case but three cases, a 164 
case with hyperintense CN III on T2W and isointense on FLAIR, and two cases with 165 
isointense on T2W and hypointense on FLAIR were noted. Contrast enhancement was 166 
present in all but two cases (n = 12, 86%), being marked in six cases (n = 6, 43%). When 167 
present, the contrast enhancement was focal in eight cases (n = 8, 67%) and diffuse in the 168 
rest (n = 4, 33%). In all cases, the anatomical region of the lesion was at the level of the 169 
middle cranial fossa; however, in some cases with diffuse enhancement, the lesion 170 
extended into the orbital fissure (n = 3, 21%).  171 
 172 
Other findings 173 
Comprehensive haematology and biochemistry were available in 13 cases and were 174 
unremarkable in all. Thyroid function was evaluated in three dogs and was determined 175 
within normal limits in all cases. One patient (Case 7) had been previously diagnosed 176 
with hypothyroidism; however, the dog was receiving thyroid hormone supplementation 177 
and the thyroid values were within normal limits at presentation. Thoracic radiographs 178 
and abdominal ultrasonography were performed in seven patients and were unremarkable 179 
in all. Cerebrospinal fluid was collected from the cerebellomedullary cistern in 13 dogs 180 
(Appendix 1). The mean (SD) and median (range) nucleated cell count was 1.99 cells/uL 181 
(2.06) and 1 cells/uL (0 to 8 cells/uL), respectively. The nucleated cell count was elevated 182 
in two patients (n = 2, 14%), with 6 and 8 cells/uL (reference range 0-5 cells/uL) 183 
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respectively. The nucleated cellular population consisted in scattered small/medium 184 
lymphocytes and monocytes in all cases, apart from Case 14 were the main population of 185 
cells were hypersegmented non-degenerated neutrophils. The mean (SD) and median 186 
(range) CSF total protein were 0.30 g/L (0.17) and 0.25 g/L (0.19 to 0.80 g/L), 187 
respectively. The total protein was elevated in one patient (n = 1, 7%; reference range 0-188 
0.35 g/L; Case 14). Polymerase chain reaction for canine distemper virus, Toxoplasma 189 
gondii and Neospora caninum were negative in blood and CSF in all dogs tested (n = 9, 190 
64%). 191 
 192 
Treatment and Follow-up 193 
The treatment and follow-up information is detailed in Appendix 3. Anti-inflammatory to 194 
immunosuppressive doses of systemic corticosteroid (prednisolone at 1 mg/kg once to 195 
twice daily) was started at presentation in seven dogs (n = 7, 50%). Only two dogs 196 
showed improvement of the clinical signs while under systemic corticosteroid treatment 197 
(n = 2, 29%; Cases 4 and 14). Case 10 developed severe gastrointestinal side effects 198 
within the first week of treatment and the medication was discontinued at that point. The 199 
neurological signs in this dog improved three weeks after the systemic corticosteroid 200 
treatment was discontinued. Case 9 showed improvement of the clinical signs three 201 
months after discontinuation of the systemic corticosteroid treatment. Furthermore, three 202 
dogs without systemic corticosteroid treatment (n = 3, 43%; Cases 6, 7 and 12) improved 203 
two weeks to four months after their presentation. In the other seven dogs the clinical 204 
signs remained unchanged, three received a course of systemic steroid therapy and four 205 
had no treatment. 206 
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Six-month follow-up MRI scan was available in two cases (Cases 8 and 14). In case 8, 207 
MRI findings at re-examination remained unchanged compared to presentation and 208 
clinical signs were not improved. In case 14, MRI at presentation revealed marked 209 
enlargement with marked diffuse post-contrast enhancement; however, at re-examination 210 
the follow-up MRI showed equivocal enlargement with no post-contrast enhancement 211 
(Fig. 5), and clinical signs were improved at that time.   212 
The mean (SD) and median (range) long-term follow-up time was 33.93 months (21.76) 213 
and 25 months (12 to 84 months), respectively. The external ophthalmoparesis improved 214 
in 64% cases (7/11 dogs) during this period of time and the neuromuscular strabismus 215 
resolved. The internal ophthalmoplegia/ophthalmoparesis remained unchanged in 79% 216 
cases (11/14 dogs) and partially resolved in 21% cases (3/14 dogs). The mean (SD) and 217 
median (range) time to improvement was 5.55 weeks (5.53) and 3.57 weeks (11 days to 4 218 
months) respectively, from the day the clinical signs were first noted. Follow-up of over 219 
one year with complete ophthalmic and neurological re-examination by the authors was 220 
possible in six cases. 221 
 222 
Discussion 223 
This is the first descriptive study of idiopathic oculomotor neuropathy in dogs. The 224 
presumptive diagnosis of idiopathic neuropathy was made in all cases based on the failure 225 
on revealing an underlying cause. A putative association between cranial neuropathy and 226 
hypothyroidism has been stated in the veterinary literature,18,19 however this is not borne 227 
out by other studies.17,20 None of the dogs of this study showed clinical signs of 228 
hypothyroidism and the thyroidal function was normal in the three dogs tested. One case 229 
 Tetas Pont et al. VRU 2017 
had been previously diagnosed with hypothyroidism; however, the authors think that 230 
there is unlikely association between the hypothyroidism and the oculomotor neuropathy 231 
due to the fact that at the time of the onset of the clinical signs (oculomotor neuropathy) 232 
the dog did not reveal any clinical signs consistent with hypothyroidism and the thyroid 233 
function was controlled. Infectious causes of neuropathy are exceptionally rare in dogs,2 234 
and none of the dogs tested in this report for canine distemper virus, Toxoplasma gondii 235 
and Neospora caninum were positive. In this study, the lack of clinical deterioration in all 236 
cases and the clinical improvement in several dogs might indicate the presence of an 237 
underlying oculomotor neuritis with subsequent permanent nerve damage. Furthermore, 238 
the MRI findings (CN III enlargement with contrast enhancement) and the mildly 239 
elevated cell count in CSF (in two dogs) could support this hypothesis. However, this 240 
hypothesis could not be confirmed due to the lack of histopathology and for this reason 241 
the term idiopathic neuropathy was adopted. Surgical biopsy at this area carries high 242 
operative morbidity due to the location and to the authors’ knowledge this surgical 243 
approach has not been attempted in dogs. 244 
All cases in this study presented with mydriasis, and only two dogs retained some 245 
pupillary response to light at presentation. On the other hand, external ophthalmoparesis 246 
was only seen in some dogs. The oculomotor parasympathetic axons are located 247 
superficially on the medial side of CN III,1 subsequently if the neuropathy initiates in this 248 
location it is likely that only the parasympathetic component will be affected. The clinical 249 
signs were unilateral in all dogs in this study, similar to the reported canine cases of 250 
idiopathic facial neuropathy but different to trigeminal neuropathy.13-17 There are several 251 
cases published of unilateral idiopathic trigeminal neuropathy in dogs,21 however the 252 
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majority are bilaterally affected.13 Bilateral trigeminal neuropathy commonly presents 253 
with sudden inability to close the mouth;13 on the other hand, unilateral trigeminal 254 
neuropathy may only manifest with unilateral transitory masticatory muscle atrophy.2 255 
Subsequently, it is possible that unilateral cases of trigeminal neuropathy of the 256 
mandibular branch are overlooked by owners and veterinarians if the atrophy is mild or 257 
transitory. The mean recovery time of motor function was five weeks in the present 258 
study, similar to other idiopathic cranial neuropathies;13,14,16 however, a third of the cases 259 
affected with CN III motor dysfunction (4/11 dogs) in our study showed no signs of 260 
improvement. This finding differs from trigeminal neuropathy where the motor function 261 
recovered in all cases;13 but similar to facial neuropathy, where resolution of clinical 262 
signs was only seen in half of the affected dogs.14,15,16 Some degree of mydriasis persisted 263 
in all cases in our study; however, almost a quarter of patients recovered partial CN III 264 
parasympathetic function. Medical treatment with corticosteroids did not appear to alter 265 
the course of the disease in this study, even though the dose used and length of course 266 
varied. Further studies are required to prove the efficacy of corticosteroids for the 267 
treatment of idiopathic oculomotor neuropathy, however corticosteroid therapy does not 268 
appear to change the clinical outcome of other cranial neuropathies.13,22 269 
A total of 22 cases of canine ophthalmoplegia/ophthalmoparesis (internal, external or 270 
both) are published in the veterinary literature.3-12 Of these 22 cases, only three report 271 
isolated CN III deficits,5,8,10 the rest of the reports describe dogs with multiple cranial 272 
nerve dysfunction as part of middle cranial fossa syndrome (also known as cavernous 273 
sinus syndrome) or other neurological signs.3-7,9,11,12 The middle cranial fossa is a paired 274 
depression of the basiphenoid bone, located between the rostral and caudal cranial fossa 275 
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at the base of the skull.1 Multiple cranial nerves travel through the middle cranial fossa 276 
including the oculomotor, trochlear and abducens nerves, as well as the three branches of 277 
the trigeminal nerve.1 These cranial nerves exit/enter the skull through the orbital fissure 278 
(oculomotor nerve, trochlear nerve, abducens nerve and ophthalmic branch of the 279 
trigeminal nerve), round foramen (maxillary branch of the trigeminal nerve), or oval 280 
foramen (mandibular branch of the trigeminal nerve).1 The middle cranial fossa 281 
syndrome is a well-recognised syndrome in dogs characterised by variable impairment of 282 
these nerves.2 In the veterinary literature, this syndrome is usually referred to as 283 
cavernous sinus syndrome.3,4,6,7,9,10 However, this term should ideally be discarded, 284 
because these cranial nerves are not directly related to the cavernous sinus.2 Twelve of 22 285 
dogs published in the veterinary literature showed unilateral deficits,3-8,10-12 two cases 286 
presented with unilateral signs and became bilateral within days,4,6 and six cases had 287 
bilateral deficits at presentation.4,5,9 All cases were reported to be secondary to neoplasia 288 
at the level of the middle cranial fossa or orbital fissure.3-12 Ten dogs were euthanized at 289 
presentation,3-5,7,10,12 and for the rest, the mean life expectancy after diagnosis was 7.1 290 
months3,4,6,8-10 with the longest survival time of 18 months.6 Clinical signs deteriorated 291 
over this period of time in all cases, precipitating euthanasia.3,4,6,8-10 For this reason, the 292 
inclusion criteria of the current study demanded a minimal follow-up time of 12 months 293 
and only dogs with no deterioration of the neurological signs were included.  294 
Magnetic resonance is the diagnostic imaging modality of choice in veterinary medicine 295 
for diseases affecting cranial nerves.23 Magnetic resonance provides superior resolution 296 
of the retrobulbar and intracranial CN III pathway compared to computed tomography.23 297 
In this study, MRI enabled an accurate and detailed morphological assessment of the 298 
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lesions in all cases, only two dogs had equivocal enlargement of the CN III and no post-299 
contrast enhancement on MRI. Localization and extension of the lesions were in 300 
accordance with the neuroanatomic localization is all cases, and six months follow-up 301 
MRI was possible in two. Based upon the location, shape, invasiveness, signal intensity, 302 
homogeneity, and enhancement properties of the lesion, MRI features can help the 303 
differentiation between neoplastic and inflammatory disorders in cranial nerves 304 
dysfunction.21,24,25 Human patients that have cranial nerve enhancement following 305 
contrast medium administration, but do not have an associated mass are considered to 306 
have cranial neuritis or ganglionitis rather than neoplasia.25 Similarly in veterinary 307 
medicine, dogs with trigeminal neuritis confirmed postmortem had diffuse enlargement 308 
of the nerve without a mass lesion.21 In the present study, six cases had marked 309 
enlargement of the CN III with mass effect in the surrounding tissue; three of these had 310 
diffuse enhancement in most of the length of the CN III, and the other marked focal 311 
enlargement of the nerve that could be considered a neoplastic lesion based on previously 312 
published literature. The pathogenesis of the disease in this study remains currently 313 
obscure, however, no deterioration of the clinical sings, no involvement of other cranial 314 
nerves or general condition was noted in any the dogs with a follow-up time of 20 to 41 315 
months, which would be expected with a neoplastic lesion over that length of time. 316 
Therefore, we could conclude that idiopathic oculomotor neuropathy is not indicative of a 317 
serious underlying disorder. 318 
The main limitations of this study include the low number of cases, lack of pathologic 319 
confirmation, lack of standardized MRI protocols and heterogeneous nature of the study 320 
design.   Results could be more definitively supported with a prospective multi-center 321 
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study. Futures studies could also evaluate the sensitivity and specificity of MRI for 322 
detecting CN III abnormalities in dogs with idiopathic oculomotor neuropathy. Moreover, 323 
MRI features (including a more objective measurement for cranial nerve enlargement) 324 
could be evaluated as prognostic factors for regaining full CN III function. The lack of 325 
histopathology was unavoidable due to the non-fatal nature of this condition and the high 326 
morbidity that a surgical biopsy could carry due to the location of the lesion.  The authors 327 
applied stringent inclusion criteria for sampled animals in the current study in order to 328 
maximize the likelihood of a true positive diagnosis as much as possible. 329 
 330 
In conclusion, findings from the current study supported including idiopathic oculomotor 331 
neuropathy as a differential diagnosis for dogs presenting with unilateral 332 
ophthalmoplegia/ophthalmoparesis (internal, external, or both) with the absence of other 333 
neurological and ophthalmic signs, and with MRI lesions restricted to CN III. These cases 334 
can have a good prognosis as the clinical signs do not deteriorate or can even improve 335 
without treatment.  336 
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Appendices 421 
Appendix 1. Clinical Findings for Dogs with Ophthalmoplegia/ophthalmoparesis and 422 
Presumed Idiopathic Oculomotor Neuropathy.  423 
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 424 
Footnote: Be, Beagle; BC, Border Collie; BT, Border Terrier; Bx, Boxer; CNIII, third 425 
cranial nerve; CSF, cerebrospinal fluid; FE, female entire; FN, female neutered; Gh, 426 
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Greyhound; GR, Golden Retriever; LR, Labrador Retriever; ME, male entire; MN, male 427 
neutered; RC, Rough Collie; SBT, Staffordshire Bull Terrier; We, Weimaraner. 428 
*, in Case 13 the mydriasis was noted a month prior to presentation and the 429 
neuromuscular strabismus two years before. 430 
 431 
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 433 
Appendix 2. Magnetic Resonance Findings for Dogs with 434 
Ophthalmoplegia/ophthalmoparesis Associated with Presumed Idiopathic Oculomotor 435 
Neuropathy. 436 
 437 
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Footnote: CNIII, third cranial nerve (oculomotor nerve); Hyper, hyperintensive; Hypo, 439 
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hypointensive; Iso, isointense; MCF, middle cranial fossa; MRI, magnetic resonance 440 
imaging; N/A, not available; OF, orbital fissure. 441 
 442 
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Appendix 3. Treatment, Progression and Follow-up for Dogs with 445 
Ophthalmoplegia/ophthalmoparesis Associated with Idiopathic Oculomotor Neuropathy.  446 
 447 
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Footnote: CNIII, third cranial nerve (oculomotor nerve); FU, follow-up; MRI, magnetic 448 
resonance imaging. 449 
 450 
  451 
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 452 
Figure legends 453 
 454 
 455 
 456 
Figure 1. Mydriasis secondary to internal ophthalmoplegia, and upper eyelid ptosis and 457 
neuromuscular strabismus (dorsolateral) secondary to external ophthalmoparesis of the 458 
left eye in a nine and a half-year-old male entire Staffordshire Bull Terrier (Case 12). 459 
 460 
 Tetas Pont et al. VRU 2017 
 461 
 462 
Figure 2. Transverse magnetic resonance images obtained at the level of the pituitary 463 
gland (asterisk) in a seven-year-old male neutered Golden Retriever presented with 464 
internal ophthalmoplegia and external ophthalmoparesis of the left eye (Case 10). There 465 
is equivocal enlargement and isointensity of the left oculomotor nerve on T2W (A), on 466 
FLAIR (B), and on T1W pre-contrast (C) with no enhancement of left oculomotor 467 
following contrast administration (D).  468 
 Tetas Pont et al. VRU 2017 
 469 
Figure 3. Transverse magnetic resonance images obtained at the level of the pituitary 470 
gland (asterisk) in a seven-year-old female neutered Boxer presented with internal 471 
ophthalmoplegia and external ophthalmoparesis of the left eye (Case 7). There is mild 472 
enlargement of the left oculomotor nerve with hyperintensity on T2W (arrow; A), 473 
hyperintensity on FLAIR (arrow; B), and isointensity on T1W pre-contrast (arrow; C) 474 
with mild focal heterogeneous enhancement following contrast administration (arrow; D). 475 
 Tetas Pont et al. VRU 2017 
 476 
Figure 4. Transverse magnetic resonance images obtained at the level of the pituitary 477 
gland (asterisk) in a six-year-old male neutered Beagle presented with internal 478 
ophthalmoplegia and external ophthalmoparesis of the right eye (Case 11). There is 479 
marked enlargement of the right oculomotor nerve with isointensity on T2W (arrow; A), 480 
hypointensity on FLAIR (arrow; B), and isointensity on T1W pre-contrast (arrow; C) 481 
with marked focal homogeneous enhancement following contrast administration (arrow; 482 
D). 483 
 484 
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 485 
Figure 5. Transverse magnetic resonance images obtained at the level of the head of the 486 
caudate nucleus (asterisk) in a three and a half-year-old female neutered Weimaraner 487 
presented with internal ophthalmoplegia and external ophthalmoparesis of the left eye 488 
(Case 14). There is marked enlargement of the left oculomotor nerve with isointensity on 489 
T2W (arrow; A) and isointensity on T1W pre-contrast (arrow; B), with marked diffuse 490 
homogeneous enhancement following contrast administration (arrow; C) at presentation. 491 
At six-moth follow-up scan, there is resolution of the magnetic resonance findings (D-F). 492 
 493 
